– UK, Cambridge – 4basebio PLC (LON:4BB), which develops and commercializes the large-scale manufacture of synthetic DNA as well as nanoparticle delivery solutions, announced the appointment of Alan Malus to its Board as Independent Non-executive Director as of 16 December 2024.
About Alan Joseph Malus
Alan Malus has over 18 years of experience in life sciences and diagnostics, having most recently served as Corporate EVP and President of the Laboratory Products and Services Segment at Thermo Fisher Scientific. He joined Thermo Fisher in 1998, holding numerous executive positions including President of Analytical Technologies Group, President of Lab Products Group, and President of Customer Channels Group. Before this, Alan Malus spent nearly 15 years in the automotive industry, working with Ford, Chrysler, and Textron Inc., where he served as VP of Finance.
Since 2023, Alan Malus has been a Director at Industrial Physics Inc. He also serves as Director at Azenta Life Sciences. Previously, he served as a Director at PHC Holdings Corporation in Japan (2021 to 2022).
Alan Malus graduated from the University of Michigan in 1981, starting his career as a financial analyst at Ford in 1984 and moving to Chrysler in 1986.
About 4basebio
4basebio is an innovation-driven life biotechnology company focused on accelerating the development of advanced therapy medicinal products (ATMPs) through its high-performance synthetic DNA products and non-viral, cell-targeting nucleic acid delivery platform. The Company’s objective is to become a market leader in the manufacture and supply of high-quality synthetic DNA products for research, therapeutic, and pharmacological use as well as the development of target-specific non-viral vectors for the efficient delivery of payloads in patients.
For more information: https://www.4basebio.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.